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Background: Mechanisms regulating 
transcription of MLCK are poorly defined.  
Results: Deleting a CArG element from the 
mylk1 gene specifically decreased expression of 
the 130kDa smMLCK isoform, resulting in 
decreased intestinal contractility and 
proliferation.  
Conclusion: The 130kDa smMLCK isoform has 
functions that cannot be compensated for by the 
220kDa MLCK. 
Significance: Floxed mylk1 mice permit specific 
functions of the 130kDa smMLCK to be 
determined. 
SUMMARY	  
The mylk1 gene encodes a 220kDa nonmuscle 
myosin light chain kinase (MLCK), a 130kDa 
smooth muscle MLCK (smMLCK), as well as 
the non-catalytic product telokin. Together 
these proteins play critical roles in regulating 
smooth muscle contractility. Changes in their 
expression are associated with many 
pathological conditions, thus it is important 
to understand the mechanisms regulating 
expression of mylk1 gene transcripts. 
Previously, we reported a highly conserved 
CArG box, which binds serum response 
factor, in intron15 of mylk1. As this CArG 
element is near to the promoter that drives 
transcription of the 130kDa smMLCK, we 
examined its role in regulating expression of 
this transcript. Results show that deletion of 
the intronic CArG region from a β-
galactosidase reporter gene abolished 
transgene expression in mice in vivo. 
Deletion of the CArG region from the 
endogenous mylk1 gene, specifically in smooth 
muscle cells, decreased expression of the 
130kDa smMLCK by 40% without affecting 
expression of the 220kDa MLCK or telokin. 
This reduction in 130kDa smMLCK 
expression resulted in decreased 
phosphorylation of myosin light chains, 
attenuated smooth muscle contractility and a 
24% decrease in small intestine length that 
was associated with a significant reduction of 
Ki67-positive smooth muscle cells. Overall, 
these data show that the CArG element in 
intron 15 of the mylk1 gene is necessary for 
maximal expression of the 130kDa smMLCK 
and that the 130kDa smMLCK isoform is 
specifically required to regulate smooth 
muscle contractility and small intestine 
smooth muscle cell proliferation.   
The mylk1 gene is a large gene spanning ~250kb, 
comprising 31 exons (1). Mylk1 encodes at least 
three protein products: a 220kDa MLCK, a 
130kDa MLCK, and a non-catalytic gene 
product, telokin. Each transcript from the mylk1 
gene is derived from a unique independent 
promoter within the gene (1). The 220kDa 
MLCK is also referred to as nonmuscle MLCK 
or endothelial MLCK, as it was first 
characterized in chick embryo fibroblasts and 
endothelial cells (2,3). The 130kDa MLCK is 
also called the smooth muscle MLCK 
(smMLCK), since it is most abundant in smooth 
muscle tissues, however, it is also widely 
expressed in other tissues at lower levels (1,4,5). 
Telokin is a non-catalytic product of the gene 
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that is expressed at very high levels in intestinal, 
urinary, and reproductive tract smooth muscle, 
at low levels in vascular smooth muscle cells 
and undetectable levels in other tissues (6). 
In the presence of Ca2+ and calmodulin, both the 
220kDa and 130kDa smMLCK can 
phosphorylate serine 19 of the 20kDa myosin 
regulatory light chain (RLC) of smooth muscle 
and nonmuscle myosin II. In smooth muscle 
cells, phosphorylation of the myosin regulatory 
light chain is an obligatory step for the initiation 
of contraction. In many other cell types, 
phosphorylation of RLC induced by MLCK is 
important for regulating actomyosin-based 
cytoskeletal functions such as focal adhesion 
and stress fiber formation, secretion, cytokinesis, 
neurite growth cone advancement, endothelial 
and epithelial barrier formation and cell 
migration (7-13). Alterations in MLCK 
expression have been linked to a variety of 
pathologies, including colitis (14), inflammatory 
bowel disease (15), asthma (16,17), 
inflammatory lung disease (18), familial aortic 
dissection (19) and hypertension (20,21). The 
specific functions of the various MLCK 
isoforms in these processes, however, are not 
clear. Global knockout of the 220kDa MLCK in 
mice results in numerous defects in epithelial 
and endothelial barrier function, suggesting that 
this isoform has a specific role in regulating 
these processes (22-26). Through specific 
targeting of a portion of the catalytic domain 
shared by the 220 and 130kDa MLCKs, it has 
been possible to determine the combined roles of 
these kinases in specific tissues and cell types 
(27). As anticipated, ablation of both MLCK 
isoforms in smooth muscle cells resulted in 
impaired contractility and decreased myosin 
light chain phosphorylation (20,27). Surprisingly, 
deletion of both 220kDa and 130kDa smMLCK 
specifically from endothelial cells had very little 
effect on vascular permeability, bringing into 
question the importance of endothelial cell 
expressed MLCK in regulating endothelial 
barrier function (28). Because of the overlapping 
structure of the 220kDa and 130kDa smMLCK 
it is difficult to examine the function of the 
130kDa smMLCK, without also affecting 
expression of the 220kDa isoform. To address 
this issue, we examined regulatory elements that 
specifically regulate expression of the 130kDa 
smMLCK with the hypothesis that deletion of 
these elements may attenuate expression of the 
130kDa smMLCK without effecting expression 
of the other products of the mylk1 gene. Toward 
this goal, we previously identified a promoter 
within intron 14 of the mylk1 gene that 
specifically directs expression of the 130kDa 
smMLCK (29). Within this promoter there is a 
conserved CArG element that binds to serum 
response factor (SRF) and is required for 
myocardin-induced expression of the 130kDa 
MLCK (29). 
The CArG element, CC(A/T)6GG, is the cis-
regulatory element that binds  serum response 
factor (SRF), an evolutionarily conserved 
MADS (MCM1, agamous, deficiens, SRF) 
domain-containing transcription factor. SRF 
binding and crystal structure studies have shown 
that a functional CArG element can deviate by 
no more than 1 bp from the consensus sequence 
(30). Virtually all known CArG elements reside 
within 4 kb of the transcription start site of genes 
(30). Using computational algorithm prediction 
approaches with experimental validation, a 
genome-wide screen identified 60 target genes 
that are regulated by CArG elements. Among 
these, 26 of the validated SRF target genes 
encode for cytoskeletal/contractile or adhesion 
proteins (30,31). When bound to a CArG 
element, SRF also provides a docking surface 
for interaction with numerous accessory co-
factors to form ternary complexes, conferring 
tissue- or pathway-specific expression of target 
genes. For example, ternary complexes of SRF 
and Elk1 are important for growth factor 
regulation of immediate early genes such as c-
fos (32). In smooth muscle cells, ternary 
complexes of SRF together with myocardin or 
myocardin related transcription factors are very 
powerful activators of numerous smooth muscle-
specific contractile and regulatory proteins such 
as the 130kDa smMLCK (33). SRF and 
myocardin enhanced the activity of the 130kDa 
smMLCK promoter reporter genes and induced 
expression of the 130kDa smMLCK in 10T1/2 
fibroblast cells, while GATA-6 repressed 
promoter activity, possibly through disrupting 
SRF-myocardin complexes (29). Besides the 
CArG element in the promoter region there is 
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another highly conserved CArG element in the 
first intron of the 130kDa smMLCK (intron 15 
of mylk1 gene). Chromatin immunoprecipitation 
assays confirmed that this intronic CArG 
element also binds to SRF in vivo in smooth 
muscle cells (29). However, the previous studies 
did not determine if this intronic CArG element 
affects the expression of the 130kDa smMLCK 
in vivo. Here, we found that the intronic CArG 
element is important for regulating expression of 
transgenes driven by the 130kDa smMLCK 
promoter in vivo and for driving expression of 
endogenous 130kDa smMLCK in mice. 
Moreover, we show that targeting this element is 
an effective means to specifically decrease 
expression of the endogenous 130kDa smMLCK 
without affecting expression of the 220kDa 
MLCK or telokin. 
EXPERIMENTAL PROCEDURES 
Generation of targeting vector for homologous 
recombination 
An mylk1 targeting vector was generated by 
inGenious Targeting Laboratory (Stony Brook, 
NY). A 7.56kb fragment containing about 5.1kb 
extending 5’ and 2.16kb extending 3’ to the 
intronic CArG region, was subcloned from a 
C57BL/6 BAC clone (RP23: 55O1, Source 
BioScience, UK) into pSP72 vector (Promega). 
To construct the targeting vector for 
homologous recombination, a loxP/FRT flanked 
Neo cassette was inserted 54bp 3’ of the intronic 
CArG element, and a single loxP site containing 
engineered Afl II and BamH I sites for southern 
blot analysis was inserted 184bp 5’ of the 
intronic element.  
Generation of transgenic reporter mice 
The neomycin resistance cassette was removed 
from the targeting vector described above by Flp 
recombinase mediated recombination in bacteria. 
The vector was then digested by Fse I and Pml I 
to yield a 2.3kb fragment that included the 
intronic CArG element and surrounding loxP 
sites. The 130kDa smMLCK promoter, exon 1, 
intron 1 and portion of exon 2 were cut from the 
pGL2B construct described previously (29) and 
ligated into the pWhere lacZ reporter vector 
(InvivoGen). The smMLCK -389~+8427 pWhere 
vector was then cut by Fse I and Pml I. The 
resulting 2kb fragment that included the intronic 
CArG element was replaced with the 
corresponding 2.3kb fragment isolated from the 
targeting vector to generate the ICArG-smMLCK-
389~+8427 pWhere plasmid. The integrity of the 
plasmid was confirmed by restriction enzyme 
digestion and DNA sequencing. In order to 
delete the CArG element from the ICArG-
smMLCK-389~+8427 pWhere plasmid it was 
introduced into bacteria expressing Cre 
recombinase to generate plasmid ΔICArG-
smMLCK-389~+8427 pWhere. Correct excision of 
the CArG element was confirmed by DNA 
sequencing. ICArG-smMLCK-389~+8427 pWhere and 
ΔICArG-smMLCK-389~+8427 pWhere plasmids were 
linearized and microinjected into pronuclei of 
fertilized oocytes by standard procedures by the 
Indiana University School of Medicine 
transgenic mouse facility. Neonatal founder 
mice were genotyped for the presence of the 
transgene and were analyzed at one month old 
by β-galactosidase staining as described 
previously (34). All animal experiments were 
conducted under the approval of Indiana 
University School of Medicine Institutional 
Animal Care and Use Committee.  
Generation of knockout mice 
Knockout mice were generated by inGenious 
Targeting Laboratory (Stony Brook, NY). The 
targeting construct was linearized using NotI 
prior to electroporation into C57BL/6N 
embryonic stem cells. Positively selected ES 
cells were screened by PCR and then expanded 
for southern blot confirmation of targeting. 
Correctly targeted ES cells were microinjected 
into BALB/c blastocysts. Resulting chimeras 
with a high percentage black coat color were 
mated to C57BL/6 Flpe mice to remove the Neo 
cassette. The deletion of Neo cassette was 
screened and confirmed by PCR and DNA 
sequencing. Germline floxed mice were mated 
to smMHC-Cre mice (from Michael Kotlikoff at 
Cornell)(also on a C57BL/6 background) to 
delete the intronic CArG region specifically in 
smooth muscle tissues. Genotyping primers are: 
MLCK P1: GGC AAG CCA AAC CCT TAC 
ACA, MLCK P2: GAC TGG AGA TAA CCT 
CCT CTC ACT, Cre F: CCA ATT TAC TGA 
CCG TAC ACC, Cre R: GTA CGT GAG ATA 
TCT TTA ACC CTG AT. For further analysis 
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of the recombined flox allele primer P2 was 
used in combination with MLCK P3: GGA TGT 
GAG CTG CGC TTC TGA G. 
Contractility measurement of isolated colon 
rings 
The proximal part of the colon (with intact 
epithelial layer) was cut into rings 0.5 cm in 
length and contractility measured as described 
previously (35). A 1.5-g preload amount was 
empirically determined to result in the optimal 
contraction. To induce colon smooth muscle 
contraction, colon rings were challenged with 60 
mM KCl or 1 µM carbachol, a muscarinic 
agonist. 
Contractility measurement of isolated thoracic 
aorta 
Thoracic aortas (with intact endothelium) were 
dissected carefully and their branches were 
ligated with thread before being used. The aortas 
were connected to a PSS-filled tube that was 
pressurized with a regulator to inflate the vessels 
to the desired pressure before chemical 
stimulation. A pressure transducer (SPR-524, 
Microtip catheter transducer, Millar) was used to 
monitor the intraluminal pressure, and a volume 
compensator used to compensate for water 
transport across the vessel wall. The vascular 
contraction during endothelin 1 stimulation was 
measured as changes in intra-luminal pressure 
(36). 
Quantitative RT-PCR 
Total RNAs were extracted from colon smooth 
muscle (the epithelial layer was removed by 
scraping), whole bladder and thoracic aorta of 6 
weeks old control and smooth muscle-specific 
130kDa MLCK knockout mice. The mRNA 
expression levels were quantitated by reverse 
transcription-qPCR as described previously (37). 
Because the 130kDa smMLCK transcript has a 
unique 5’ UTR region not present in the 220kDa 
MLCK transcript, we were able to design 
primers to specifically detect the 130kDa 
smMLCK mRNA. The primers used are: 
220kDa MLCK F: GAA CCT CTG CAT CAA 
AGA AGG AG, 220 MLCK R: GAT GGC TTG 
CCC TTT TCT GTG CCA TG, 130kDa 
smMLCK F: CTC TTG CTA CTT TCT CTT 
TTT CCT TCA CTG, smMLCK R: CTG GTC 
TCC ACC CGT CTC TTC AAC AG, Telokin F: 
GAC ACC GCC TGA GTC CAA CCT CCG, 
Telokin R: GGC TTT TCC TCA GCA ACA 
GCC TCC. 
Western blot analysis 
Total protein lysates from colon smooth muscle 
(epithelial layer removed by scraping) and 
whole bladder were extracted and analyzed as 
described previous (37). Antibodies used for 
detecting MLCK were a polyclonal antibody 
raised against the common carboxyl-terminus of 
MLCK and telokin (CT polyclonal) (38) and a 
polyclonal antibody raised against the full length 
bovine smMLCK (FL polyclonal) (39). Vinculin 
was used as loading control (V4505, clone VIN-
11–5, Sigma Aldrich). 
MLC phosphorylation 
The proximal portion of the colon (epithelia 
intact) was cut into 0.5cm-long circular rings, 
and the rings were hung in an organ bath, as 
described above for contractility measurements 
of colon. Tissues were flash frozen in the basal 
non-contracted status or at the peak of 
contraction induced by 60 mM KCl. The 
phosphorylation levels of myosin light chain 
(MLC) were analyzed by Western blotting of 
proteins separated on urea/glycerol gels, as 
described previously (40). 
Cell proliferation 
The intestines of littermate neonatal mice (day 
9-10) were dissected and the lowest portions of 
the ileum were incubated in 20% sucrose in PBS 
solution overnight at 4°C. Tissue samples were 
frozen into Tissue-Tek O.C.T. compound 
(Cat#4583, Sakura) and 7µm sections were cut. 
Sections were fixed with 3.7% formaldehyde, 
permeablized in 0.2% triton X-100 and blocked 
with 10% FCS in 50mMTris pH7.6, 150mM 
NaCl, then incubated with antibodies against 
Ki67 (Cat#15580, Abcam, 1:500) and smooth 
muscle α-actin (Cat#A2547, Sigma, 1:500). 
Primary antibodies were visualized by 
incubation with rhodamine-conjugated Goat 
anti-Rabbit IgG (Jackson ImmunoResearch, 
1:50) and FITC-conjugated Donkey anti-mouse 
IgG (Jackson ImmunoResearch, 1:50) secondary 
antibodies.  
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Statistical analysis 
Chi-square test was used to determine if the 
observed birth frequency of knockout mice was 
lower than expected. For other statistical 
comparison, student’s t-tests were performed 
(Prism, GraphPad Software, CA). A value of 
p<0.05 was considered statistically significant. 
RESULTS 
Deletion of an intronic CArG element in the 
mylk1 gene abolished transgene expression 
driven by the 130kDa smMLCK promoter. 
Previously we reported a highly conserved 
CArG element located in intron 15 of the mylk1 
gene (1st intron of the 130kDa smMLCK) (29). 
To investigate the role of this intronic region in 
regulating 130kDa smMLCK gene expression, 
we generated transgenic mice in which a lacZ 
reporter was driven by the 130kDa smMLCK 
promoter, exon1, intron1 and a portion of exon 2 
with (ICArG-smMLCK-389~+8427 pWhere) or 
without (ΔICArG-smMLCK-389~+8427 pWhere) this 
intronic CArG region, as described in Methods. 
In 2 of the 3 independent founders harboring the 
wild type transgene, high levels of β-
galactosidase staining were observed in visceral 
smooth muscle rich tissues, such as bladder, 
colon, small intestine and ureters (Figure 1). The 
third line had lower levels of expression but in a 
similar pattern (not shown). One of the 2 high 
expressing founders also exhibited staining in 
bronchi as well as in the lung and small vessels 
of skeletal muscle and liver (Figure 1). In 
contrast to the wild type transgenes, no β-
galactosidase expression could be detected in 
any of 7 founder mice harboring the CArG 
deleted transgene (Figure 1). Weak background 
staining seen in bladder, kidney and colon is 
similar to that seen in non-transgenic mice 
(Figure 1, lower right panel). These data 
demonstrate that the intronic CArG region is 
critical for expression of a 130kDa smMLCK-
driven transgene.  
Deletion of the intronic CArG region from the 
endogenous mylk1 gene resulted in decreased 
expression of the 130kDa smMLCK. To 
determine if deletion of the intronic CArG 
region would decrease expression of the 
endogenous 130kDa smMLCK, we crossed mice 
harboring the floxed CArG region with mice 
expressing Cre recombinase under the control of 
the smooth muscle myosin heavy chain 
promoter (Figure 2) (41). We have previously 
shown that this Cre transgene results in high 
levels of recombination specifically in smooth 
muscle tissues (42). PCR analysis of genomic 
DNA isolated from colon and aorta of knockout 
and control mice further showed that there is 
more efficient recombination of the floxed allele 
in colon smooth muscle as opposed to aortic 
smooth muscle (Figure 2B). Although the 
recombined allele was readily detectable in both 
tissues there also remained significant amounts 
of the non-recombined floxed allele. The latter 
likely represents a combination of less than 
100% efficiency of recombination, together with 
contamination from other cell types in the 
sample. Of note, we did not detect the 
recombined allele in the majority (about 75%) of 
our control flox/flox mice. This is in contrast to 
a previous report, which showed that transient 
expression of Cre recombinase driven by the 
smMHC promoter in sperm resulted in 
recombination of the floxed allele derived from 
the male Cre-positive parent in almost all mice 
(43). Recombination of the floxed allele in 
sperm results in progeny that are CArGf/- (global 
heterozygous) rather than the expected CArGf/f. 
Both control (Cre-/-CArGf/f and Cre-/- CArGf/-) 
and smooth muscle-specific CArG knockout 
(Cre-/+ CArGf/f and Cre-/+ CArGf/-) mice reached 
adulthood without any obvious growth and 
behavioral abnormalities. However, knockout 
mice were born with a slightly lower than 
expected frequency of 19% as compared to 25% 
(Chi-square test p=0.033, degree of freedom=1, 
Figure 2C). This suggests that deletion of the 
intronic CArG region from the native gene 
results in partial embryonic lethality or neonatal 
death. Quantitative real-time RT-PCR showed 
that there is an approximately 40% decrease in 
130kDa smMLCK mRNA levels of CArGf/f Cre-
/+ knockout mice compared with control CArGf/f 
Cre-/- mice, while there was no significant 
alteration in 220kDa MLCK or telokin mRNA 
expression levels (Figure 3A). Similar results 
were seen when CArGf/- Cre-/+ knockout mice 
were compared with CArGf/- Cre-/- control mice. 
As we did not see any significant differences in 
130kDa smMLCK expression between the two 
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control strains (CArGf/f Cre-/- and CArGf/- Cre-/-), 
and our standard genotyping does not 
distinguish between these strains, in all 
subsequent experiments control mice were a 
mixture of CArGf/f Cre-/- and CArGf/- Cre-/-. 
Similarly, all smooth muscle-specific knockout 
mice were a mixture of CArGf/f Cre-/+ and 
CArGf/- Cre-/+. 
Similar to colon, we observed approximately 
40% and 30% reductions in 130kDa smMLCK 
mRNA levels in the bladder and aorta of 
knockout mice, respectively (Figure 3B). 
Moreover, using an antibody to the common 
carboxyl-terminus of MLCK and telokin, we 
found that deletion of the intronic CArG region 
reduced 130kDa smMLCK protein expression 
by approximately 30% and 40% in colon and 
bladder, respectively (Figure 3C,D). Similar 
findings were observed using an MLCK 
antibody raised against the full-length bovine 
smMLCK (Figure 3D).  Additional experiments 
confirmed that the presence of the loxP sites in 
the control mice did not alter 130kDa smMLCK 
expression compared to wild type mice (Figure 
3E-G).  
Deletion of the intronic region and subsequent 
decreases in 130kDa smMLCK expression 
attenuated smooth muscle contractility. In order 
to investigate whether the decreased expression 
of the 130kDa smMLCK affects the contractility 
of both visceral and vascular smooth muscle, we 
analyzed the contractility of colon and aortic 
segments, ex vivo. Contraction elicited by high 
KCl-induced depolarization of colon from 
knockout mice was dramatically decreased 
compared with control mice (Figure 4A,C). 
Similarly carbachol induced contractions were 
also impaired in tissue from knockout mice 
(Figure 4B,C). The L-type calcium channel 
inhibitor diltiazem blocked the contractile 
responses to high KCl in all mice (data not 
shown). ET1-mediated contraction of aortic 
segments was also decreased in knockout mice 
compared with controls (Figure 4D).  
Decreased contraction of smooth muscle tissues 
in knockout mice was associated with decreased 
myosin light chain phosphorylation. The 
130kDa smMLCK induces contraction of 
smooth muscle by phosphorylating the 
regulatory myosin light chain. Thus, we sought 
to determine if the impaired contractile 
responses seen in the knockout mice were 
associated with altered myosin light chain 
phosphorylation. Under basal resting conditions, 
levels of MLC phosphorylation in both control 
and knockout mice were very low and showed 
no significant difference (Figure 4E).  However, 
at the peak of contraction induced by high KCl, 
the level of phosphorylation of the MLC in 
knockout mice was much less than that seen in 
control mice (18.3% as compared to 39.3%, 
Figure 4E). 
Decreased 130kDa smMLCK expression 
resulted in shortened small intestine. Further 
analysis of both control and knockout mice 
showed that the length of small intestine was 
shorter by about 24% in the intronic CArG 
knockout mice, while the length of colon was 
not significantly different (Figure 5A, B). The 
shorter small intestine was not associated with 
any change in body weight (Figure 5C). We also 
did not detect any inflammation in knockout 
mice as determined by lack of changes in 
expression of inflammatory genes, IL1β, IL6, 
CCL2, Trem1 or CXCL10 (Figure 5D). 
Immunofluorescence staining of cross-sections 
of ileum from neonatal mice for the cell 
proliferation marker Ki67 revealed that there 
were fewer positively stained smooth muscle 
cells in both circular and longitudinal smooth 
muscle layers of knockout mice (Figure 6).  
DISCUSSION 
Results of this study clearly show that a CArG 
box-containing region in intron 15 of the mylk1 
gene is required for expression of the 130kDa 
smMLCK. Deletion of this intronic CArG box 
attenuated expression of the 130kDa smMLCK 
without affecting expression of either the 
220kDa MLCK or telokin. Moreover, decreased 
expression of only the 130kDa smMLCK in 
smooth muscle tissues attenuated smooth muscle 
contractility, which was associated with 
decreased myosin light chain phosphorylation 
and impaired small intestine smooth muscle cell 
proliferation. This demonstrates that the 130kDa 
smMLCK isoform is specifically required to 
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regulate not only smooth muscle contraction, but 
also intestinal smooth muscle cell proliferation.  
Deletion of both the 220kDa and 130kDa 
MLCK from smooth muscle tissues has been 
previously shown to impair contractility, myosin 
light chain phosphorylation and gastrointestinal 
motility in mice (27). The current studies 
suggest that it is primarily the 130kDa 
smMLCK rather than the 220kDa MLCK that is 
responsible for regulating contraction in 
gastrointestinal smooth muscle. This is 
consistent with the lack of reported effects on 
smooth muscle contractility in the 220kDa 
MLCK knockout mice (44). Results also suggest 
that the 130kDa smMLCK has a specific role in 
regulating the proliferation of small intestinal 
smooth muscle cells during early neonatal 
growth (Figure 6). Although MLCK and myosin 
light chain phosphorylation are known to be 
important in cell division, these are the first data 
that suggest a specific role for the 130kDa 
smMLCK isoform in this process. This 
conclusion should, however, be viewed with 
caution as it is possible that the alterations in 
proliferation are secondary to impaired 
contractility. In vascular, airway and bladder 
smooth muscle, mechanical strain can induce 
smooth muscle cell proliferation (45-47). A 
decreased mechanical stimulus in CArG 
knockout mice may thus also impair intestinal 
smooth muscle cell proliferation resulting in 
attenuated intestinal elongation. 
Deletion of the intronic CArG region completely 
abrogated expression of a 130kDa smMLCK-
lacZ reporter transgene in the visceral smooth 
muscle tissues, whereas deletion of this element 
from the endogenous gene only decreased 
endogenous 130kDa smMLCK expression by 
about 40%. The relatively small decrease in 
130kDa smMLCK expression may be partially 
due to incomplete recombination of the floxed 
alleles by Cre recombinase. In support of this, 
PCR analysis of genomic DNA isolated from 
colon and aorta demonstrate variable levels of 
floxed alleles remaining in these tissues (Figure 
2B). Alternatively, it is also possible that the 
reporter transgene is missing additional positive 
cis-acting regulatory elements that play a role in 
regulating expression of the endogenous 130kDa 
smMLCK. In support of this possibility, a notch 
responsive element has been identified at -3687 
that plays an important role in activating 130kDa 
smMLCK expression in vascular smooth muscle 
cells (48). This element is not present in the 
reporter genes described in our study, which 
extend from -389 to +8427. This may also 
explain why the reporter genes exhibited very 
low levels, or undetectable, lacZ expression in 
vascular smooth muscle tissues (Figure 1). 
Although the endogenous 130kDa smMLCK is 
expressed at lower levels in many nonmuscle 
tissues, we did not observe significant levels of 
lacZ transgene expression in many of these 
tissues. This may simply reflect the sensitivity of 
lacZ detection or the nonnative chromatin 
environment of reporter transgenes. Although 
the transgenic reporter mice were generated 
using a pWhere lacZ expression vector that is 
CpG-free and has H19 insulator elements 
flanking the transgene, we have previously 
shown that the telokin promoter also does not 
drive high levels of expression in many founder 
mice generated using this transgene vector (34). 
As the promoter and regulatory elements 
analyzed are embedded within introns of the 
larger mylk1 gene it is possible that transcription 
from the promoters that drive expression of the 
220kDa MLCK may modulate the chromatin 
structure of the gene to facilitate the activity of 
these internal elements. Although analysis of 
reporter genes suggest that the promoter and first 
intron of the 130kDa smMLCK are not 
sufficient to fully recapitulate expression of the 
endogenous 130kDa MLCK, deletion of the 
intronic CArG region from the endogenous gene 
decreases 130kDa smMLCK expression by 40%. 
This demonstrates that this element is required 
for full activation of the gene. The region 
deleted following Cre recombinase mediated 
recombination of the lacZ reporter or the 
endogenous mylk1 gene includes a conserved 
CArG box together with almost 300bp of 
flanking sequence. The CArG element is located 
within a region of 63bp that is highly conserved 
between species (29).  Analysis using rVista 
identified conserved potential binding sites for 
the transcription factors SRF, Lun1, HoxA3, Oct, 
AP3, SRY and DBP in this region. This raises 
the possibility that the decreased 130kDa 
smMLCK seen following deletion of this region 
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may be due to loss of not only SRF binding but 
also one or more of these other transcription 
factors. For example, Lun1, also named 
topoisomerase I binding, arginine/serine-rich, E3 
ubiquitin protein ligase (TOPORS), is 
particularly interesting in this regard, as this 
protein also has sumo ligase activity and both 
SRF and myocardin are know to be regulated by 
sumoylation (49-51). This raises the possibility 
that Lun1 may further regulate SRF and 
myocardin activity to control expression of the 
130kDa smMLCK. 
We have previously shown that a CArG element 
within the telokin promoter is also critical for 
expression of telokin transcripts through analysis 
of transgenic reporter mice and targeting the 
endogenous telokin promoter (52,53). Together 
with the current findings these data show that 
SRF plays a key role in regulating expression of 
multiple transcripts from the mylk1 gene. 
Although polymorphisms in these CArG 
elements have not yet been linked to diseases, an 
amplification of a CT repeat adjacent to the 
CArG element in the promoter of the 130kDa 
smMLCK in SHR rats has been proposed to 
increase 130kDa smMLCK expression and be 
the cause of the hypertension in these rats (21). 
A single nucleotide polymorphism (SNP) in 
intron 17 of the human MYLK1 gene (equivalent 
to intron 15 in mouse) has also been shown to 
regulate 130kDa smMLCK expression and to be 
linked to inflammatory lung disease (54). As this 
SNP is not in the conserved region deleted in the 
current study these data suggest that there may 
be multiple important regulatory elements within 
this intron of the mylk1 gene.  
Although SRF is important for regulating 
expression of both 130kDa smMLCK and 
telokin transcripts, it does so by binding to 
distinct CArG elements. These elements appear 
to be functionally separated from each other, as 
deletion of a single CArG element affects 
expression of one transcript but not the other. 
Deletion of the CArG element in the telokin 
promoter (in mylk intron 28) abolished telokin 
expression without affecting expression of 
transcripts encoding the 200kDa or 130kDa 
smMLCKs (52). Similarly, deletion of the CArG 
element from intron 1 of the 130kDa smMLCK 
gene (in mylk1 intron 15) decreased expression 
of the 130kDa smMLCK without affecting 
expression of the 220kDa MLCK or telokin 
(Figure 3). These data suggest that either the 
CArG elements are simply too far from the other 
promoters to affect their activity (e.g. the telokin 
CArG element is about 73kb from the 130kDa 
smMLCK promoter) or that there are perhaps 
insulator elements within the mylk1 gene that 
restrict the activity of the elements to specific 
promoters. Additional studies are required to 
resolve these possibilities. 
In summary, data from both transgenic reporter 
mice and a knockout mouse model demonstrate 
that a CArG region within intron 15 of the mylk1 
gene plays an important role in specifically 
regulating expression of 130kDa smMLCK. 
Moreover, the ICArG flox mice provide a novel 
model system for further interrogating the 
specific functions of the 130kDa smMLCK 
isoform in different cell types in vivo. 
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FIGURE LEGENDS 
Figure 1. Comparison of transgene expression in reporter mice. A. Organs were harvested from one 
month old reporter mice harboring the ICArG-smMLCK-389~+8427 pWhere transgene (shown schematically at 
the top) and lacZ expression was examined by X-Gal staining (blue/green color. n=3). Yellow triangle, 
loxP site; black triangle, Frt site; blue box, intronic CArG element; red box, promoter CArG element. B. 
β-galactosidase expression in organs harvested from 1 month old mice harboring the ΔICArG-smMLCK-
389~+8427 pWhere transgene (schematic, upper panel) in which the intronic CArG element is deleted 
(images are representative of 7 founder mice). Lower right panel shows β-galactosidase staining of colon 
from a nontransgenic mouse as a negative control (Negative colon).  
Figure 2. Generation of the intronic CArG knockout mice. A. Schematic representation of approach 
used to delete the intronic CArG region from the endogenous mylk1 gene. The native mylk1 gene is 
shown at the top with the targeting vector below it. Numbers above the native gene refer to nucleotides 
positions relative to the transcription start site of the 130kDa smMLCK. The promoter and intronic CArG 
boxes are indicated (red and blue boxes, respectively). Yellow triangles, loxP sites; black triangles Frt 
sites. Below the targeting vector are schematic representations of the correctly targeted allele (Flox+Neo), 
the targeted allele following Flpe-mediated removal of the neomycin cassette (Flox) and the deleted allele 
generated following cre-mediated recombination (Deleted allele). Positions of primers used for 
genotyping are indicated. B. Ethidium bromide stained agarose gel showing an example of PCR analysis 
of recombination of the intronic CArG element using primers P3 and P2 (Panel A) and genomic DNA 
isolated from colon smooth muscle and aortic tissues. The bands corresponding to the Floxed (F) and 
recombined or deleted (Δ) alleles and an internal loading control (IC) are indicated. C. Breeding scheme 
used to generate knockout mice together with the genotypes of the progeny, their expected frequency, 
observed frequency and total numbers of pups analyzed. 
Figure 3. The expression of the 130kDa smMLCK is decreased in CArG knockout mice. A. Smooth 
muscle layers were isolated from the colon of control (CArGf/f Cre-/-: FF), (CArGf/- Cre-/-: F-) and 
knockout (CArGf/f  Cre-/+: FF KO) and (CArGf/-  Cre-/+: F- KO) mice and total RNA was harvested. mRNA 
levels were measured by qRT-PCR. Transcript levels were normalized to hprt internal loading control and 
relative expression levels (RQ) are shown. Relative expression = 2-ΔCt, where ΔCt = (Ctexpt – Cthprt). Each 
column represents the mean±SEM of samples obtained from 5-14 mice. *, p<0.05. B. mRNA levels in 
bladder and thoracic aorta from control (CArGf/f Cre-/- + CArGf/- Cre-/- combined: Ctrl)  and knockout 
(CArGf/f  Cre-/+ + CArGf/-  Cre-/+ combined: KO) mice were measured by qRT-PCR. Transcript levels were 
quantitated as described in panel A. Each column represents the mean±SEM of samples obtained from 
11-13 mice. *, p<0.05. C. Representative western blot of 130kDa smMLCK and vinculin in colon and 
bladder from two control (C) and two knockout (KO) mice. D. Quantitation of western blots using 
different antibodies for smMLCK. Data were normalized to Vinculin levels and are expressed relative to 
expression levels in control mice.  CT Ab: a polyclonal antibody raised against the common carboxyl-
terminus of MLCK and telokin, FL Ab: a polyclonal antibody, raised against the full-length bovine 
smMLCK. n=11-13. *, p<0.05. E. Western blot analysis and quantitation (F) of 130kDa smMLCK 
protein expression in bladder tissue from wild type (CArG+/+ Cre-/-: WT) and CArGf/f Cre-/- (FF) mice. G. 
qRT-PCR analysis of 130kDa smMLCK mRNA expression in bladder and colon smooth muscle from 
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wild type (CArG+/+ Cre-/-: WT) and flox/flox (CArGf/f Cre-/-: FF) mice. No significant differences in 
130kDa smMLCK expression were observed. n=4(bladder). N=7(colon) 
Figure 4. Smooth muscle contractility and myosin light chain phosphorylation are decreased in 
knockout mice. A-B. Colon rings were hung in an organ bath and stimulated to elicit contraction with 
60mM KCl or 1µM Carbachol as described in methods. Data shown are the mean±SEM changes in 
tension over time of 20 rings from control (CArGf/f Cre-/- + CArG f/- Cre-/-: Ctrl) mice and 12 from 
knockout (CArGf/f Cre-/+ + CArGf/- Cre-/+: KO) mice. C. The average changes in peak contractile responses 
of colonic rings from control (Ctrl) and knockout (KO) mice. n=20 for control, n=12 for knockout. *, 
p<0.05. D. Mean maximal contractile responses of thoracic aortic to increasing doses (M) of Endothelin 1 
(ET1). n=6 for control, n=5 for knockout. *, p<0.05. E. Colon rings were either flash frozen under resting 
conditions or challenged by 60mM KCl and flash frozen at the peak of contraction. Unphosphorylated 
and phosphorylated myosin light chains were separated by urea/glycerol gel electrophoresis and 
visualized by western blotting. A representative western blot is shown in the left panel. (un-P, 
unphosphorylated MLC; P, phosphorylated MLC; C, CArGf/f Cre-/- and CArG f/- Cre-/- control; KO, 
CArGf/f Cre-/+ and CArGf/- Cre-/+). The ratios of MLC-P to total MLC under basal conditions (n=6) and 
after KCl stimulation (n=10) were calculated and the mean values±SEM are plotted in the right panel. *, 
p<0.05. 
Figure 5. Knockout mice have shorter small intestines.  A. Representative pictures and B, quantitative 
data showing the lengths of colon and small intestine of adult control (CArGf/f Cre-/- + CArG f/- Cre-/-: Ctrl) 
and knockout (CArGf/f Cre-/+ + CArGf/- Cre-/+: KO) mice. n=5. *, p<0.05. C. Body weights of adult control 
and knockout mice. N=6. D. qRT-PCR analysis of inflammatory cell markers in smooth muscle from the 
small intestine of control or knockout mice. Transcript levels were quantitated as described in figure 3. n= 
3-5 No significant differences in expression were observed in control and knockout mice. 
Figure 6. Knockout mice have decreased intestinal smooth muscle cell proliferation. A. Ki67 (red) 
and smooth muscle α-actin (green) staining of cross sections of the lower portion of small intestines from 
neonatal control (CArGf/f Cre-/- + CArG f/- Cre-/-: Ctrl) and knockout (CArGf/f Cre-/+ + CArGf/- Cre-/+: KO) 
mice. White arrows and white arrow heads point to examples of Ki67 positive smooth muscle cells in the 
circular and longitudinal smooth muscle layers, respectively. B. Quantitation of the number of positive 
Ki67 smooth muscle cells per field at 40x magnification in the circular layer, longitudinal layer and both 
smooth muscle layers of the small intestine. n=6-7 mice. *, p<0.05.  
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